METHODS: Overall, 4991 UCUB patients who underwent RC were abstracted. The cumulative survival estimates were used to generate conditional survival rates. Cox regression analyses were performed for prediction of cancer-specific mortality (CSM), according to duration of survivorship.
RESULTS: The five-year CSM-free survival rate was 63.9% at RC, and increased to 71.0%, 77.5%, 81.7%, 85.9% and 86.3% in patients who survived ⩾1, 2, 3, 4 and 5years, respectively. Patients with pT2-4 disease benefitted from the highest increase in survivorship two years after RC. The same findings were recorded according to patients' nodal status.
CONCLUSION: The survival of the first two years after RC markedly improves individual patient prognosis. The prognostic gains differ according to patient and tumour characteristics.
Written by:
Sun M, Abdollah F, Bianchi M, Trinh QD, Shariat SF, Jeldres C, Tian Z, Hansen J, Briganti A, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Are you the author?
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
Reference: Eur J Cancer. 2011 Dec 21. Epub ahead of print.
doi: 10.1016/j.ejca.2011.11.024
PubMed Abstract
PMID: 22196034
UroToday.com Bladder Cancer Section
